○Sayaka Ogi¹, Hidetoshi Sunamoto¹, Hirohiko Fukiya¹, Hayato Nishiyama¹, Futoshi Nara¹, Kazuhiro Onuma¹ (1. Pharm. Res. Lab., UBE Inds. Ltd.)

○Shota Kaseda^1,2, Yuya Sannomiya¹, Jun Kuwazuru¹, Sayaka Ogi³, Ryoko Sasaki¹, Hidetoshi Sunamoto³, Hirohiko Fukiya³, Hayato Nishiyama³, Misato Kamura^1,2, Saki Niinou¹, Jun Horizono¹, Yuimi Koyama¹, Mary Ann Suico¹, Kazuhiro Onuma³, Futoshi Nara³, Tsuyoshi Shuto¹, Hirofumi Kai¹ (1. Grad. Sch. Pharm Sci., Kumamoto Univ., 2. HIGO program., Kumamoto Univ., 3. Pharm. Res. Lab., UBE Inds. Ltd.)

○Iqbal Julian¹, Takuya Iwamoto^1,2 (1. Department of Clinical Pharmaceutics, Graduate School of Medicine, Mie University, 2. Department of Pharmacy, Mie University Hospital)

○Takehiro Nakano¹, Hiroshi Watanabe¹, Tadashi Imafuku¹, Motoko Tanaka², Kazutaka Matsushita², Masafumi Fukagawa³, Hitoshi Maeda¹, Toru Maruyama¹ (1. Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan, 2. Akebono Clinic, Kumamoto, Japan, 3. Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan)

○Shiomi Naito¹, Yoichi Sunagawa^1,2,3, Yusuke Miyazaki¹, Masafumi Funamoto¹, Kana Shimizu¹, Satoshi Shimizu¹, Sari Nurmila¹, Yasushi Katanasaka^1,2,3, Atsushi Imaizumi⁴, Tadashi Hashimoto⁴, Koji Hasegawa³, Tatsuya Morimoto^1,2,3 (1. Sch. Pharm. Sci., Univ. of Shizuoka, 2. Shizuoka. General Hosp., 3. Kyoto Med. Ctr., NHO, 4. Therabiopharma)